Table 1.
Data description: summary of patient characteristics from the ADNI and the clinical trials of the CAMD and ADCS cohorts
| Study | Sample size | Gender (% Females) | APOE (% ε4 positive) | ADAS-Coga | Study duration |
|---|---|---|---|---|---|
| ADNI | 1275 | 41.7 | 58.7 | 14.2 ± 8.5 | 8 years |
| CAMD-1105 | 325 | 51.0 | - | 25.2 ± 12.2 | 20 months |
| CAMD-1131 | 57 | 59.6 | - | 20.5 ± 3.6 | 24 weeks |
| CAMD-1132 | 412 | 43.4 | 38.0 | 19.1 ± 3.1 | 51 weeks |
| CAMD-1140 | 137 | 42.3 | - | 19.1 ± 3.4 | 24 weeks |
| CAMD-1141 | 492 | 55.3 | - | 9.9 ± 6.0 | 23 months |
| CAMD-1142 | 405 | 56.0 | 64.1 | 25.3 ± 10.4 | 18 months |
| ADCS-HU [18] | 210 | 64.4 | 65.2 | 27.1 ± 10.8 | 24 months |
| ADCS-DHA [19] | 402 | 52.5 | 57.7 | 23.9 ± 9.0 | 18 months |
| ADCS-VN [20] | 300 | 63.1 | 71.3 | 30.1 ± 9.8 | 24 months |
| ADCS-HC [21] | 409 | 53.9 | 70.0 | 22.6 ± 8.6 | 18 months |
| ADCS-LL [22] | 406 | 59.9 | 55.3 | 23.9 ± 10.5 | 18 months |
| ADCS-MCI [67] | 769 | 47.0 | 53.0 | 11.03 ± 4.2 | 26 months |
ADNI Alzheimer’s Disease Neuroimaging Initiative, CAMD Coalition against Major Diseases, ADCS Alzheimer’s Disease Cooperative Study, APOE apolipoprotein-E, HU Huperzine, DHA Docosahexaenoic Acid, VN Valproate Neuroprotection, HC Homocysteine, LL Simvastatin, MCI Mild Cognitive Impairment
aSummary total ADAS-Cog scores are represented as mean ± standard deviation